GlobalData’s director of therapy research & analysis in medical devices says the new entity could make an attractive ...

CEO Tom Polen said BD will “double down on shifting our portfolio, both organically and inorganically through tuck-in M&A, ...

Becton Dickinson & Co. closed 9.83% short of its 52-week high of $251.99, which the company reached on February 3rd.

The board of directors of Franklin Lakes-based, global medical technology company BD, has unanimously authorized BD management ...

BD plans to separate its Biosciences and Diagnostic Solutions unit into an independent company by fiscal 2026.

Becton Dickinson & Co. said it’s planning to separate part of its life sciences segment in a move aimed at raising the medical technology company’s stock.

Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...

BDX's overall topline in the first quarter of fiscal 2025 continues to benefit from revenue growth in all segments.

Q1 2025 Management View Tom Polen emphasized several key updates, including the planned separation of BD’s Biosciences and Diagnostic Solutions businesses, which aims to create two strategically ...

Earnings Per Share (EPS) of $3.43, beating the estimated $3 and showing significant growth from the previous year’s $2.68. Revenue reached approximately $5.17 billion, surpassing the estimated $5.10 ...

Becton, Dickinson and Company (NYSE:BDX) authorized to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions ...